Insider Trading Alert - LTBR, THRM And AST Traded By Insiders

Yesterday, Sept. 16, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $4,488,945.00.

Highlighted Stocks Traded by Insiders:

Lightbridge (LTBR) - FREE Research Report

Mushakov Andrey, who is EVP - Intl Nuclear Operations at Lightbridge, bought 5,000 shares at $0.89 on Sept. 16, 2015. Following this transaction, the EVP - Intl Nuclear Operations owned 102,409 shares meaning that the stake was boosted by 5.13% with the 5,000-share transaction.

The shares most recently traded at $0.94, up $0.05, or 5.32% since the insider transaction. Historical insider transactions for Lightbridge go as follows:

  • 4-Week # shares bought: 5,250
  • 12-Week # shares bought: 17,750
  • 24-Week # shares bought: 39,257

The average volume for Lightbridge has been 209,500 shares per day over the past 30 days. Lightbridge has a market cap of $17.2 million and is part of the basic materials sector and chemicals industry. Shares are down 38.92% year-to-date as of the close of trading on Wednesday.

Lightbridge Corporation operates as a nuclear fuel technology company worldwide. It operates in two segments, Technology and Consulting. The company engages in the design and development of proprietary nuclear fuels.

Exclusive Offer: Get the latest Stock Analysis on LTBR - FREE

TheStreet Quant Ratings rates Lightbridge as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself. Get the full Lightbridge Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gentherm (THRM) - FREE Research Report

Phillips Kenneth John, who is VP & General Counsel/Secretary at Gentherm, sold 4,624 shares at $46.58 on Sept. 16, 2015. Following this transaction, the VP & General Counsel/Secretary owned 24,000 shares meaning that the stake was reduced by 16.15% with the 4,624-share transaction.

The shares most recently traded at $48.32, up $1.74, or 3.6% since the insider transaction. Historical insider transactions for Gentherm go as follows:

  • 4-Week # shares sold: 6,300
  • 12-Week # shares sold: 23,708
  • 24-Week # shares sold: 23,708

The average volume for Gentherm has been 356,000 shares per day over the past 30 days. Gentherm has a market cap of $1.7 billion and is part of the consumer goods sector and automotive industry. Shares are up 32.11% year-to-date as of the close of trading on Wednesday.

Gentherm Incorporated designs, develops, manufactures, and sells thermal management technologies and cable systems worldwide. It operates in two segments, Automotive and Industrial. The company has a P/E ratio of 22.2. Currently, there are 6 analysts who rate Gentherm a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on THRM - FREE

TheStreet Quant Ratings rates Gentherm as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Gentherm Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Asterias Biotherapeutics (AST) - FREE Research Report

Lebkowski Jane, who is President of R&D at Asterias Biotherapeutics, sold 4,912 shares at $6.00 on Sept. 16, 2015. Following this transaction, the President of R&D owned 476 shares meaning that the stake was reduced by 91.17% with the 4,912-share transaction.

Spink Katharine E., who is VP and Chief Operating Officer at Asterias Biotherapeutics, sold 3,760 shares at $6.00 on Sept. 16, 2015. Following this transaction, the VP and Chief Operating Officer owned 0 shares meaning that the stake was reduced by 100% with the 3,760-share transaction.

Wirth Edward, who is Chief Medical Officer at Asterias Biotherapeutics, sold 2,880 shares at $6.00 on Sept. 16, 2015. Following this transaction, the Chief Medical Officer owned 0 shares meaning that the stake was reduced by 100% with the 2,880-share transaction.

The shares most recently traded at $5.52, down $0.48, or 8.7% since the insider transaction. Historical insider transactions for Asterias Biotherapeutics go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 20,000

The average volume for Asterias Biotherapeutics has been 350,200 shares per day over the past 30 days. Asterias Biotherapeutics has a market cap of $220.0 million and is part of the health care sector and drugs industry. Shares are up 75.85% year-to-date as of the close of trading on Wednesday.

Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. It is developing pluripotent stem-cell therapeutic products in the areas of neurology and oncology. Currently, there are 2 analysts who rate Asterias Biotherapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AST - FREE

TheStreet Quant Ratings rates Asterias Biotherapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Asterias Biotherapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

The U.S. Economy Is 'Stronger Than Most People Realize': LIVE BLOG

The U.S. Economy Is 'Stronger Than Most People Realize': LIVE BLOG

Goldman Takes Wall Street Trading Title After Sputtering Last Year

Goldman Takes Wall Street Trading Title After Sputtering Last Year

Stocks Push to Session Highs During Fed Chair's Congressional Testimony

Stocks Push to Session Highs During Fed Chair's Congressional Testimony

This Under the Radar Stock Picker Tells Jim Cramer He Is Bullish on Citigroup

This Under the Radar Stock Picker Tells Jim Cramer He Is Bullish on Citigroup

Morgan Stanley Profit Surges 38% on Trading Revenue, Tax Cuts

Morgan Stanley Profit Surges 38% on Trading Revenue, Tax Cuts